Monoclonal antibodies against PD-1 and PD-L1 have shown response in NSCLC patients; however, the combination of mTOR inhibitors and anti-PD-1 antibodies showed enhanced anti-tumor efficacy in pre-clinical models of NSCLC and colorectal cancer [100,101]. This evidence concerns the gene CD274 and neoplasm.